Cargando…

Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy

Detalles Bibliográficos
Autores principales:	Annunzio, Kaitlin, Cackovic, Michael, Bond, David, Sawalha, Yazeed, Voorhees, Timothy J., Hanel, Walter, Alinari, Lapo, Baiocchi, Robert, Reneau, John, Brammer, Jonathan, Maddocks, Kami, Christian, Beth, Epperla, Narendranath
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196908/ https://www.ncbi.nlm.nih.gov/pubmed/36287222 http://dx.doi.org/10.1182/bloodadvances.2022008621

Ejemplares similares

Impact of circulating lymphoma cells at diagnosis on outcomes in patients with Waldenstrom macroglobulinemia
por: Nalin, Ansel, et al.
Publicado: (2023)

Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study
por: Fleming, Megan, et al.
Publicado: (2022)

Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas
por: Fleming, Megan, et al.
Publicado: (2022)

Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents
por: Faisal, Muhammad Salman, et al.
Publicado: (2023)

P1071: COMBINATION OF PD-1 INHIBITION WITH IMMUNOMODULATORY DRUG TREATMENT IN HODGKIN AND LARGE B-CELL LYMPHOMA: RESULTS FROM A PHASE I/II STUDY
por: Bond, David, et al.
Publicado: (2023)

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
por: Hanel, Walter, et al.
Publicado: (2023)

Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date
por: Sawalha, Yazeed, et al.
Publicado: (2020)

Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data
por: Sawalha, Yazeed, et al.
Publicado: (2020)

Emerging therapies in mantle cell lymphoma
por: Hanel, Walter, et al.
Publicado: (2020)

Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies
por: Hanel, Walter, et al.
Publicado: (2021)

Novel targeted therapies for mantle cell lymphoma
por: Alinari, Lapo, et al.
Publicado: (2012)

Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma
por: Choueiry, Fouad, et al.
Publicado: (2021)

Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches
por: Hanel, Walter, et al.
Publicado: (2022)

Emerging treatment options for the management of Hodgkin’s lymphoma: clinical utility of nivolumab
por: Bond, David A, et al.
Publicado: (2017)

Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma
por: Sircar, Anuvrat, et al.
Publicado: (2023)

Diffuse Large B-cell Lymphoma Presenting as Bilateral Renal Masses: Successful Treatment with Dose-adjusted REPOCH (Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy Regimen
por: Kaur, Anahat, et al.
Publicado: (2019)

Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study
por: Epperla, Narendranath, et al.
Publicado: (2023)

Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study
por: Annunzio, Kaitlin, et al.
Publicado: (2023)

A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells
por: Hanel, Walter, et al.
Publicado: (2022)

Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas
por: Braunstein, Zachary, et al.
Publicado: (2022)

Survival of patients with transformed follicular lymphoma in the United States: a multiple cohort study
por: Vaughn, John L., et al.
Publicado: (2023)

DA-REPOCH Versus R-CHOP for the Treatment of Activated B-Cell Subtype Diffuse Large B-Cell Lymphoma: A Community Center Experience
por: Knouse, Phillip, et al.
Publicado: (2020)

Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma
por: Bond, David A., et al.
Publicado: (2019)

Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
por: Denlinger, Nathan M, et al.
Publicado: (2018)

Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions
por: Reneau, John C., et al.
Publicado: (2022)

Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasone
por: Epperla, Narendranath, et al.
Publicado: (2015)

Nonbiological factors affecting outcomes in adolescents and young adults with lymphoma
por: Dhir, Aditi, et al.
Publicado: (2023)

Sjögren’s syndrome and Neuromyelitis Optica spectrum disorders (NMOSD) – a case report and review of literature
por: Jayarangaiah, Apoorva, et al.
Publicado: (2014)

An unusual occurrence: a case of venous thromboembolism in pregnancy associated with heterotaxy syndrome
por: Epperla, Narendranath, et al.
Publicado: (2015)

Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies
por: Sawalha, Yazeed
Publicado: (2021)

Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions
por: Bond, David A, et al.
Publicado: (2021)

Racial and ethnic differences in the utilization of autologous transplantation for lymphoma in the United States
por: Vaughn, John L., et al.
Publicado: (2021)

Diagnostic dilemma: late presentation of amelanotic BRAF-negative metastatic malignant melanoma resembling clear cell sarcoma – a case report
por: Wagner, Barrett Parker, et al.
Publicado: (2013)

Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab?
por: Epperla, Narendranath, et al.
Publicado: (2020)

Transducin b-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma
por: Youssef, Youssef, et al.
Publicado: (2020)

Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant
por: Liu, Qiuying, et al.
Publicado: (2021)

Editorial: Rising Stars in Hematologic Malignancies 2021
por: Qian, Liren, et al.
Publicado: (2022)

A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models
por: Chan, Wing Keung, et al.
Publicado: (2023)

Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
por: Jain, Neeraj, et al.
Publicado: (2023)

Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy
por: Sircar, Anuvrat, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6k18oel0ctnd8efum6c9roa1mh